A Closer Look: Roche’s Move On Danoprevir Shines Light On Innovation Strategy In China
This article was originally published in PharmAsia News
Roche Pharmaceuticals Asia Pacific Head Luke Miels talks to PharmAsia News about the company’s recent deal with Ascletis, its thinking on China’s hepatitis C market and additional opportunities for out-licensing.
You may also be interested in...
Gilead and AbbVie are seen as running neck-and-neck to bring the first all-oral combo of direct-acting antivirals to market in HCV, but Gilead’s regimen is expected to win a larger market share. Idenix is starting over in the nucleoside space, but expects to bring a uridine-based “nuc” into clinical development by mid-year.
With a large patient pool and a recent expansion of government reimbursement for costly peg-interferon therapies, China is poised to see an exponential growth in its hepatitis C virus treatment market, growing north of 80% in five years, according to a recent report by research firm Decision Resources
SinoVac’s rapid antibody response, CanSino’s easier logistics requirements - plus cost advantages - make Chinese developers optimistic about supplying the world with COVID vaccines.